Archives of Pharmacal Research

, Volume 36, Issue 10, pp 1185–1188 | Cite as

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

  • Sung-Ho Kim
  • Sung-Hack Lee
  • Hyeon-Joo YimEmail author
Report on Investigational Drugs


Gemigliptin, a potent, selective and long-acting DPP 4 inhibitor was developed by LG Life Sciences and approved for use in patients with type 2 diabetes mellitus by the Korean Food and Drug Administration in June 2012 under the trade name Zemiglo®. Clinical pharmacokinetic and pharmacodynamic data suggest the efficacy and once daily dosing of gemigliptin. In clinical phase III studies, gemigliptin was efficacious as either monotherapy or combination therapy (add-on to metformin) and well tolerated in patients with type 2 diabetes. Further development of combination therapy is on-going.


Metformin Sitagliptin Vildagliptin Saxagliptin Linagliptin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was partially supported by a grant from the Ministry of Knowledge Economy (Bio-Star, 10024075).


  1. Cefalu, W.T., and S. Urquhart. 2007. Clinical management strategies for type 2 diabetes. Journal of the American Academy of Physician Assistants Suppl: 9–14.PubMedCrossRefGoogle Scholar
  2. Drucker, D.J. 2007. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30: 1335–1343.PubMedCrossRefGoogle Scholar
  3. Hwang, D.M., S.H. Kim, M.K. Yoon, O.H. Kwon, K.D. Koo, C.H. Min, S.H. Lee, J.I. Lee, C.S. Lee, H.J. Yim. 2008. LC15-0444 is a novel, potent, selective, and orally active dipeptidyl peptidase IV inhibitor. Poster presented at the annual meeting of American Diabetes Association. San Francisco: CA.Google Scholar
  4. Kim, S.E., S. Yi, K.H. Shin, T.E. Kim, M.J. Kim, Y.H. Kim, S.H. Yoon, J.Y. Cho, S.G. Shin, I.J. Jang, and K.S. Yu. 2012. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 50: 17–23.PubMedCrossRefGoogle Scholar
  5. Lankas, G.R., B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, S.K.A. Lyon, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry. 2005. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54: 2988–2994.PubMedCrossRefGoogle Scholar
  6. Lim, K.S., J.Y. Cho, B.H. Kim, J.R. Kim, H.S. Kim, D.K. Kim, S.H. Kim, H.J. Yim, S.H. Lee, S.G. Shin, I.J. Jang, and K.S. Yu. 2009. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. British Journal of Clinical Pharmacology 68: 883–890.PubMedCrossRefGoogle Scholar
  7. Lim, K.S., J.R. Kim, Y.J. Choi, K.H. Shin, K.P. Kim, J.H. Hong, J.Y. Cho, H.S. Shin, K.S. Yu, S.G. Shin, O.H. Kwon, D.M. Hwang, J.A. Kim, and I.J. Jang. 2008. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose-block-randomized, double-blind, placebo-controlled, ascending single-dose. Phase I study. Clinical Therapeutics 30: 1817–1830.PubMedCrossRefGoogle Scholar
  8. Noh, Y.H., H.S. Lim, S.J. Jin, M.J. Kim, Y.H. Kim, H.R. Sung, H.Y. Choi, and K.S. Bae. 2012. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: A crossover drug–drug interaction study in healthy male Korean volunteers. Clinical Therapeutics 34: 1182–1194.PubMedCrossRefGoogle Scholar
  9. Ohnuma, K., N.H. Dang, and C. Morimoto. 2008. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends in Immunology 29: 295–301.PubMedCrossRefGoogle Scholar
  10. Rhee, E.J., W.Y. Lee, K.H. Yoon, S.J. Yoo, I.K. Lee, S.H. Baik, Y.K. Kim, M.K. Lee, K.S. Park, J.Y. Park, B.S. Cha, H.W. Lee, K.W. Min, H.Y. Bae, M.J. Kim, J.A. Kim, D.K. Kim, and S.W. Kim. 2010. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15–0444 in patients with type 2 diabetes. Diabetes Obesity and Metabolism 12: 1113–1119.CrossRefGoogle Scholar
  11. Rhee, E.J., W.Y. Lee, K.W. Min, V.K. Shivane, A.R. Sosale, H.C. Jang, C.H. Chung, I.S. Nam-Goong, J.A. Kim, S.W. Kim. Gemigliptin Study 006 Group. 2013. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obesity and Metabolism 15: 523–530.Google Scholar
  12. Yang, S.J., K.W. Min, S.K. Gupta, J.Y. Park, V.K. Shivane, S.U. Pitale, P.K. Agarwal, A. Sosale, P. Gandhi, M. Dharmalingam, V. Mohan, U. Mahesh, D.M. Kim, Y.S. Kim, J.A. Kim, P.K. Kim, S.H. Baik. 2012. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type II diabetes. Diabetes Obesity and Metabolism 15: 410–416.Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 2013

Authors and Affiliations

  1. 1.LG Life Science R&D ParkDaejeonKorea

Personalised recommendations